On February 7, 2024 Excyte Biopharma reported after after seven years of sharpening, the Phase I clinical trial of YK012 for injection was officially launched (Press release, Excyte Biopharma, FEB 7, 2023, View Source;lang=en [SID1234646273]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

YK012 for injection is a new generation of safe, high-yield, long-acting and low-cost bispecific antibody drug independently developed by our company for the treatment of non-Hodgkin’s lymphoma (NHL), which belongs to innovative class 1 new drug. We will continue to work hard to achieve the early listing of YK012 for injection at home and abroad and benefit tumor patients!